Operating Lease, Right-of-Use Asset of Atara Biotherapeutics, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Atara Biotherapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Atara Biotherapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $10,707,000, a 77% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Atara Biotherapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,707,000 -$35,126,000 -77% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $11,027,000 -$37,921,000 -77% 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $31,727,000 -$20,254,000 -39% 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $39,807,000 -$15,128,000 -28% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $45,833,000 -$13,342,000 -23% 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $48,948,000 -$13,247,000 -21% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $51,981,000 -$13,162,000 -20% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $54,935,000 -$13,087,000 -19% 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 $59,175,000 -$11,659,000 -16% 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 $62,195,000 -$11,387,000 -15% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $65,143,000 +$46,210,000 +244% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $68,022,000 +$41,863,000 +160% 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $70,834,000 +$45,763,000 +183% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $73,582,000 +$62,034,000 +537% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $18,933,000 +$7,003,000 +59% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $26,159,000 +$13,856,000 +113% 31 Dec 2021 10-K 08 Feb 2023 2022 FY
Q3 2021 $25,071,000 +$13,002,000 +108% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $11,548,000 -$1,773,000 -13% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $11,930,000 -$1,761,000 -13% 31 Mar 2021 10-Q 04 May 2021 2021 Q1
Q4 2020 $12,303,000 -$1,704,000 -12% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $12,069,000 -$2,135,000 -15% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $13,321,000 -$1,075,000 -7.5% 30 Jun 2020 10-Q 05 Aug 2020 2020 Q2
Q1 2020 $13,691,000 -$350,000 -2.5% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 $14,007,000 +$14,007,000 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $14,204,000 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 $14,396,000 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $14,041,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-K 27 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.